Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2000-2004  (3)
  • 1
    Electronic Resource
    Electronic Resource
    Administration of anti-interleukin 18 antibody fails to inhibit development of dermatitis in atopic dermatitis-model mice NC/Nga (2003)
    Oxford, UK : Blackwell Science Ltd
    British journal of dermatology 149 (2003), S. 0 
    Details
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Summary Background Interleukin (IL)-18 has been shown to activate basophils to produce histamine and IL-4 and to induce naive T cells to differentiate into T-helper (Th) 2 cells. However, when expressed together with IL-12, IL-18 induces Th1 cell development and inhibits IgE synthesis. Previously we reported that serum IL-18 levels were elevated in the sera from atopic dermatitis-model mice NC/Nga, prior to the onset and during the development of dermatitis. Objectives We studied whether neutralization of IL-18 activity might affect dermatitis in NC/Nga mice, to investigate the role of IL-18 on dermatitis. Methods NC/Nga mice were given weekly anti-IL-18 antibody starting at 5 weeks of age to 13 weeks and development of dermatitis, scratching behaviour and serum IgE concentrations were evaluated. Results Continuous injections of anti-IL-18 antibody failed to inhibit the onset and development of dermatitis and IgE elevation. The treatment, rather, tended to lead to an exacerbation of dermatitis and scratching behaviour. In addition, the administration of anti-IL-18 antibody did not ameliorate the responsiveness of lymphocytes to IL-4, which was previously demonstrated as an immunological abnormality in the mouse. Conclusion This study demonstrates that, at least in NC/Nga mice, IL-18, although excessively expressed before the onset of dermatitis, shows antiallergic actions.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2133.2003.05406.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Oral administration of persimmon leaf extract ameliorates skin symptoms and transepidermal water loss in atopic dermatitis model mice, NC/Nga (2002)
    Oxford, UK : Blackwell Science, Ltd
    British journal of dermatology 146 (2002), S. 0 
    Details
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Summary Background  We have previously shown that persimmon leaf extract and its major flavonoid constituent, astragalin, inhibited histamine release by basophils and that oral administration of these substances prior to the onset into an atopic dermatitis (AD) model mouse, NC/Nga, prevented development of dermatitis.Objectives  This study was designed to assess the clinical therapeutic effect of persimmon leaf extract and astragalin in NC/Nga mice suffering from dermatitis and the dose–response preventive effects of persimmon leaf extract on dermatitis and transepidermal water loss (TEWL).Methods  The efficacy of persimmon leaf extract or astragalin in NC/Nga mice was judged by measurement of skin severity, scratching behaviour, serum IgE levels or TEWL.Results  Oral administration of persimmon leaf extract (250 mg kg−1) or astragalin (1·5 mg kg−1) for 4 weeks into NC/Nga mice with overt dermatitis resulted in a decrease in the severity of the condition. The preventive effect of persimmon leaf extract on the dermatitis was dose-dependent and continuous intake of persimmon leaf extract significantly decreased its onset and development. In addition, TEWL was also suppressed at a persimmon leaf extract dose of 250 mg kg−1. No significant adverse reaction by these substances could be observed.Conclusions  These observations suggest that persimmon leaf extract or the flavonoid astragalin may be alternative substances for the management of AD.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2133.2002.04557.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Endometrial carcinoma in women under 40 years of age: incidence of ovarian carcinoma and ovarian metastasis (2000)
    Springer
    International journal of clinical oncology 5 (2000), S. 109-115 
    Details
    ISSN: 1437-7772
    Keywords: Key words Endometrial carcinoma ; Younger women ; Ovarian carcinoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background. Patients under 40 years of age with endometrial carcinoma were compared with patients aged 40 years or more in terms of clinical and histopathological characteristics. Methods. One hundred and fifty-three patients with endometrial carcinoma who had their initial treatment in our hospital between 1980 and 1996 were divided into two groups; those under 40 years of age (group A) and those 40 years or more (group B). They were compared in terms of clinical stage, histological differentiation, degree of myometrial invasion, existence of lymph-vascular invasion, incidence of ovarian carcinoma with endometrial carcinoma, incidence of ovarian metastasis, treatment methods, and prognosis. Results. Fourteen patients (9.2%) were in group A and 139 patients (90.8%) in group B. There were no significant differences in the proportion of stage I patients in the two groups, but the proportion of stage IV patients was significantly higher in group A (P 〈 0.005). There were no significant differences in histological differentiation, degree of myometrial invasion, and the existence of lymph-vascular invasions. The incidence of ovarian carcinoma with endometrial carcinoma was 21.4% for group A and 2.2% for group B, being significantly higher in group A (P 〈 0.005). The incidence of simultaneous ovarian carcinoma with endometrial carcinoma was 14.2% for group A and 1.4% for group B, being significantly higher in group A (P 〈 0.05). The incidence of ovarian metastasis of endometrial carcinoma in groups A and B was 14.2% and 2.9% respectively, showing no significant difference. The incidence of either ovarian carcinoma with endometrial carcinoma or ovarian metastasis of endometrial carcinoma was significantly higher in group A (35.7%) than in group B (5%; P 〈 0.0005). There were no significant differences in the 5-year survival rates. Conclusion. Women aged under 40 years had a significantly higher incidence of ovarian carcinoma associated with endometrial carcinoma and a significantly higher incidence of either ovarian carcinoma with endometrial carcinoma or metastasis of endometrial carcinoma to the ovary than women aged 40 years or more. The 5-year survival rate showed no difference between the groups.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s101470050100
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...